Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Shares, with no par value
-
Shares outstanding
-
51M
-
Number of holders
-
14
-
Total 13F shares, excl. options
-
1.97M
-
Shares change
-
-198K
-
Total reported value, excl. options
-
$10.9M
-
Value change
-
-$1.05M
-
Number of buys
-
9
-
Number of sells
-
-5
-
Price
-
$5.76
Significant Holders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) as of Q2 2025
14 filings reported holding EPRX - EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value as of Q2 2025.
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) has 14 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.97M shares
of 51M outstanding shares and own 3.86% of the company stock.
Largest 10 shareholders include SCOTIA CAPITAL INC. (1.29M shares), Royal Bank of Canada (429K shares), GOLDMAN SACHS GROUP INC (39.8K shares), UBS Group AG (37.5K shares), BANK OF MONTREAL /CAN/ (37.3K shares), INGALLS & SNYDER LLC (37.2K shares), JPMORGAN CHASE & CO (18.7K shares), CITADEL ADVISORS LLC (18.2K shares), CIBC WORLD MARKET INC. (15K shares), and BANK OF AMERICA CORP /DE/ (12.6K shares).
This table shows the top 14 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.